Search

Your search keyword '"Wagner-Drouet, Eva-Maria"' showing total 140 results
Start Over Author "Wagner-Drouet, Eva-Maria"
140 results on '"Wagner-Drouet, Eva-Maria"'

2. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison

Author

Beelen, Dietrich Wilhelm, Iacobelli, Simona, Koster, Linda, Eikema, Dirk-Jan, van Biezen, Anja, Stölzel, Friedrich, Ciceri, Fabio, Bethge, Wolfgang, Dreger, Peter, Wagner-Drouet, Eva-Maria, Reményi, Péter, Stelljes, Matthias, Markiewicz, Miroslaw, McLornan, Donal P., Yakoub-Agha, Ibrahim, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

3. Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Author

Duque-Afonso, Jesús, Finke, Jürgen, Ngoya, Maud, Galimard, Jacques-Emmanuel, Craddock, Charles, Raj, Kavita, Bloor, Adrian, Nicholson, Emma, Eder, Matthias, Kim, Orchard, Valerius, Thomas, Snowden, John A., Tholouli, Eleni, Crawley, Charles, Collin, Matthew, Wilson, Keith M. O., Gadisseur, Alain, Protheroe, Rachel, Wagner-Drouet, Eva Maria, Savani, Bipin N., Spyridonidis, Alexandros, Ciceri, Fabio, Nagler, Arnon, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

4. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation

Author

Spyridonidis, Alexandros, Labopin, Myriam, Gedde-Dahl, Tobias, Ganser, Arnold, Stelljes, Matthias, Craddock, Charles, Wagner-Drouet, Eva Maria, Versluis, Jurjen, Schroeder, Thomas, Blau, Igor Wolfgang, Wulf, Gerald. G., Dreger, Peter, Olesen, Gitte, Sengeloev, Henrik, Kröger, Nicolaus, Potter, Victoria, Forcade, Edouard, Passweg, Jakob, de Latour, Régis Peffault, Maertens, Johan, Wilson, Keith M. O., Bourhis, Jean Henri, Finke, Juergen, Brissot, Eolia, Bazarbachi, Ali, Giebel, Sebastian, Savani, Bipin P., Nagler, Arnon, Ciceri, Fabio, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

6. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

Author

Alakel, Nael, Albring, Jörn, Berdel, Wolfgang E., Bethge, Wolfgang, Bornhäuser, Martin, Bug, Gesine, Buhl, Christoph, Call, Simon, Crysandt, Martina, Egger-Heidrich, Katharina, Eßeling, Eva, Faul, Christoph, Franke, Georg-Nikolaus, Georgi, Julia-Annabell, Glück-Wolf, Julia, Groth, Christoph, Hauptrock, Beate, Heidenreich, Daniela, Janjetovic, Snjezana, Jost, Edgar, Kaufmann, Martin, Kindler, Thomas, Klein, Stefan A., Krause, Stefan W., Kreil, Sebastian, Kretschmann, Theresa, Kunadt, Desiree, Lang, Fabian, Lenz, Georg, Martin, Sonja, Marx, Julia, Middeke, Jan-Moritz, Mikesch, Jan-Henrik, Müller, Lutz P., Müller, Nadine, Niederland, Judith, Parmentier, Stefani, Petzold, Kathrin, Platzbecker, Uwe, Rank, Andreas, Reicherts, Christian, Röllig, Christoph, Rösler, Wolf, Schäfer-Eckart, Kerstin, Schaffrath, Judith, Schaich, Markus, Schetelig, Johannes, Schliemann, Christoph, Schmid, Christoph, Schneidawind, Dominik, Schubert, Jörg, Serve, Hubert, Sockel, Katja, Steffen, Björn, Stelljes, Matthias, Teipel, Raphael, von Bonin, Malte, Wagner-Drouet, Eva, Wass, Maxi, Wendelin, Knut, Middeke, Jan Moritz, Wagner-Drouet, Eva-Maria, Müller, Lutz P, Krause, Stefan W, Klein, Stefan A, Baldauf, Henning, Stölzel, Friedrich, Petzold, Cathleen, Kriege, Oliver, Berdel, Wolfgang E, Ehninger, Gerhard, and Schmidt, Alexander H

Published
2024
Full Text
View/download PDF

7. Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party

Author

Greco, Raffaella, Hoogenboom, Jorinde D., Bonneville, Edouard F., Anagnostopoulos, Achilles, Cuoghi, Angela, Dalle, Jean-Hugues, Weissinger, Eva M., Lang, Peter, Galaverna, Federica, Martino, Massimo, Maschan, Alexei, Mauz-Körholz, Christine, Noviello, Maddalena, Passweg, Jakob, Peccatori, Jacopo, Rovira, Montserrat, Solano, Carlos, Veelken, Hendrik, Velardi, Andrea, Wagner-Drouet, Eva Maria, Zhang, Xi, Ciceri, Fabio, Bonini, Chiara, Vago, Luca, Ruggeri, Annalisa, and Chabannon, Christian

Published
2023
Full Text
View/download PDF

9. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight

Author

Schetelig, Johannes, primary, Baldauf, Henning, additional, Heidenreich, Falk, additional, Hoogenboom, Jorinde D., additional, Spellman, Stephen R., additional, Kulagin, Alexander, additional, Schroeder, Thomas, additional, Sengeloev, Henrik, additional, Dreger, Peter, additional, Forcade, Edouard, additional, Vydra, Jan, additional, Wagner-Drouet, Eva Maria, additional, Choi, Goda, additional, Paneesha, Shankara, additional, Miranda, Nuno A. A., additional, Tanase, Alina, additional, de Wreede, Liesbeth C., additional, Lange, Vinzenz, additional, Schmidt, Alexander H., additional, Sauter, Jürgen, additional, Fein, Joshua A., additional, Bolon, Yung-Tsi, additional, He, Meilun, additional, Marsh, Steven G. E., additional, Gadalla, Shahinaz M., additional, Paczesny, Sophie, additional, Ruggeri, Annalisa, additional, Chabannon, Christian, additional, and Fleischhauer, Katharina, additional

Published
2024
Full Text
View/download PDF

10. Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia

Author

Bazarbachi, Abdul Hamid, Labopin, Myriam, Kröger, Nicolaus, Brecht, Arne, Blaise, Didier, Clausen, Johannes, Fanin, Renato, Einsele, Herman, Cavanna, Luigi, Itäla-Remes, Maija, Bulabois, Claude Eric, Kündgen, Lukas, Martin, Hans, Schmid, Christof, Wagner-Drouet, Eva Maria, Alakel, Nael, Bazarbachi, Ali, Savani, Bipin, Nagler, Arnon, and Mohty, Mohamad

Published
2021
Full Text
View/download PDF

11. Allogeneic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Features in First Complete Remission As per the International Consensus Classification (ICC) 2022: A Study from the ALWP of the EBMT

Author

Nagler, Arnon, primary, Labopin, Myriam, additional, Versluis, Jurjen, additional, Sanz, Jaime, additional, Gedde-Dahl, Tobias, additional, Burns, David, additional, Schaap, Nicolaas, additional, Labussière-Wallet, Hélène, additional, von dem Borne, Peter, additional, Van Gorkom, Gwendolyn, additional, Contentin, Nathalie, additional, Neubauer, Andreas, additional, Wagner-Drouet, Eva-Maria, additional, Kroger, Nicolaus, additional, Esteve, Jordi, additional, Ciceri, Fabio, additional, and Mohty, Mohamad, additional

Published
2024
Full Text
View/download PDF

13. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

Author

Weissinger, Eva M., Metzger, Jochen, Schleuning, Michael, Schmid, Christoph, Messinger, Diethelm, Beutel, Gernot, Wagner-Drouet, Eva-Maria, Schetelig, Johannes, Baurmann, Herrad, Rank, Andreas, Stolzl, Friedrich, Schäfer-Eckart, Kerstin, Westphal, Karin, Bethge, Wolfgang, von Harsdorf, S., Bunjes, Donald W., Heidenreich, Daniela, Klein, Stefan, Holler, Ernst, Kreipe, Hans H., Jonigk, Danny, Türüchanow, Irina, Raad, Julia, Papkalla, Armin, von der Leyen, Heiko, Hambach, Lothar, Hamwi, Iyas, Ehrlich, Steve, Krauter, Jurgen, Stadler, Michael, and Ganser, Arnold

Published
2021
Full Text
View/download PDF

14. Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT

Author

Giebel, Sebastian, Labopin, Myriam, Socié, Gerard, Beauvais, David, Klein, Stefan, Wagner-Drouet, Eva Maria, Blaise, Didier, Nguyen-Quoc, Stephanie, Bourhis, Jean Henri, Thiebaut, Anne, Labussière-Wallet, Hélène, Charbonnier, Amandine, Berceanu, Ana, Diez-Martin, José Luis, Fegueux, Nathalie, Esteve, Jordi, Nagler, Arnon, and Mohty, Mohamad

Published
2021
Full Text
View/download PDF

15. Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial

Author

Hölig, Kristina, Schmidt, Helmuth, Hütter, Gero, Kramer, Michael, Teipel, Raphael, Heidrich, Katharina, Zimmer, Kristin, Heidenreich, Falk, Blechschmidt, Matthias, Torosian, Tigran, Ordemann, Rainer, Kroschinsky, Frank, Rücker-Braun, Elke, Gopsca, Laszlo, Wagner-Drouet, Eva Maria, Oelschlaegel, Uta, Schmidt, Alexander H., Bornhäuser, Martin, Ehninger, Gerhard, and Schetelig, Johannes

Published
2021
Full Text
View/download PDF

16. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

Author

Beelen, Dietrich Wilhelm, Trenschel, Rudolf, Stelljes, Matthias, Groth, Christoph, Masszi, Tamás, Reményi, Péter, Wagner-Drouet, Eva-Maria, Hauptrock, Beate, Dreger, Peter, Luft, Thomas, Bethge, Wolfgang, Vogel, Wichard, Ciceri, Fabio, Peccatori, Jacopo, Stölzel, Friedrich, Schetelig, Johannes, Junghanß, Christian, Grosse-Thie, Christina, Michallet, Mauricette, Labussiere-Wallet, Hélène, Schaefer-Eckart, Kerstin, Dressler, Sabine, Grigoleit, Goetz Ulrich, Mielke, Stephan, Scheid, Christof, Holtick, Udo, Patriarca, Francesca, Medeot, Marta, Rambaldi, Alessandro, Micò, Maria Caterina, Niederwieser, Dietger, Franke, Georg-Nikolaus, Hilgendorf, Inken, Winkelmann, Nils Rudolf, Russo, Domenico, Socié, Gérard, Peffault de Latour, Régis, Holler, Ernst, Wolff, Daniel, Glass, Bertram, Casper, Jochen, Wulf, Gerald, Menzel, Helge, Basara, Nadezda, Bieniaszewska, Maria, Stuhler, Gernot, Verbeek, Mareike, Grass, Sandra, Iori, Anna Paola, Finke, Juergen, Benedetti, Fabio, Pichlmeier, Uwe, Hemmelmann, Claudia, Tribanek, Michael, Klein, Anja, Mylius, Heidrun Anke, Baumgart, Joachim, Dzierzak-Mietla, Monika, and Markiewicz, Miroslaw

Published
2020
Full Text
View/download PDF

17. Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Author

Duque-Afonso, Jesús, primary, Finke, Jürgen, additional, Ngoya, Maud, additional, Galimard, Jacques-Emmanuel, additional, Craddock, Charles, additional, Raj, Kavita, additional, Bloor, Adrian, additional, Nicholson, Emma, additional, Eder, Matthias, additional, Kim, Orchard, additional, Valerius, Thomas, additional, Snowden, John A., additional, Tholouli, Eleni, additional, Crawley, Charles, additional, Collin, Matthew, additional, Wilson, Keith M. O., additional, Gadisseur, Alain, additional, Protheroe, Rachel, additional, Wagner-Drouet, Eva Maria, additional, Savani, Bipin N., additional, Spyridonidis, Alexandros, additional, Ciceri, Fabio, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2023
Full Text
View/download PDF

18. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation

Author

Spyridonidis, Alexandros, primary, Labopin, Myriam, additional, Gedde-Dahl, Tobias, additional, Ganser, Arnold, additional, Stelljes, Matthias, additional, Craddock, Charles, additional, Wagner-Drouet, Eva Maria, additional, Versluis, Jurjen, additional, Schroeder, Thomas, additional, Blau, Igor Wolfgang, additional, Wulf, Gerald. G., additional, Dreger, Peter, additional, Olesen, Gitte, additional, Sengeloev, Henrik, additional, Kröger, Nicolaus, additional, Potter, Victoria, additional, Forcade, Edouard, additional, Passweg, Jakob, additional, de Latour, Régis Peffault, additional, Maertens, Johan, additional, Wilson, Keith M. O., additional, Bourhis, Jean Henri, additional, Finke, Juergen, additional, Brissot, Eolia, additional, Bazarbachi, Ali, additional, Giebel, Sebastian, additional, Savani, Bipin P., additional, Nagler, Arnon, additional, Ciceri, Fabio, additional, and Mohty, Mohamad, additional

Published
2023
Full Text
View/download PDF

19. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

Author

Stelljes, Matthias, Middeke, Jan Moritz, Bug, Gesine, Wagner-Drouet, Eva-Maria, Müller, Lutz P, Schmid, Christoph, Krause, Stefan W, Bethge, Wolfgang, Jost, Edgar, Platzbecker, Uwe, Klein, Stefan A, Schubert, Jörg, Niederland, Judith, Kaufmann, Martin, Schäfer-Eckart, Kerstin, Schaich, Markus, Baldauf, Henning, Stölzel, Friedrich, Petzold, Cathleen, Röllig, Christoph, Alakel, Nael, Steffen, Björn, Hauptrock, Beate, Schliemann, Christoph, Sockel, Katja, Lang, Fabian, Kriege, Oliver, Schaffrath, Judith, Reicherts, Christian, Berdel, Wolfgang E, Serve, Hubert, Ehninger, Gerhard, Schmidt, Alexander H, Bornhäuser, Martin, Mikesch, Jan-Henrik, Schetelig, Johannes, Alakel, Nael, Albring, Jörn, Berdel, Wolfgang E., Bethge, Wolfgang, Bornhäuser, Martin, Bug, Gesine, Buhl, Christoph, Call, Simon, Crysandt, Martina, Egger-Heidrich, Katharina, Eßeling, Eva, Faul, Christoph, Franke, Georg-Nikolaus, Georgi, Julia-Annabell, Glück-Wolf, Julia, Groth, Christoph, Hauptrock, Beate, Heidenreich, Daniela, Janjetovic, Snjezana, Jost, Edgar, Kaufmann, Martin, Kindler, Thomas, Klein, Stefan A., Krause, Stefan W., Kreil, Sebastian, Kretschmann, Theresa, Kunadt, Desiree, Lang, Fabian, Lenz, Georg, Martin, Sonja, Marx, Julia, Middeke, Jan-Moritz, Mikesch, Jan-Henrik, Müller, Lutz P., Müller, Nadine, Niederland, Judith, Parmentier, Stefani, Petzold, Kathrin, Platzbecker, Uwe, Rank, Andreas, Reicherts, Christian, Röllig, Christoph, Rösler, Wolf, Schäfer-Eckart, Kerstin, Schaffrath, Judith, Schaich, Markus, Schetelig, Johannes, Schliemann, Christoph, Schmid, Christoph, Schneidawind, Dominik, Schubert, Jörg, Serve, Hubert, Sockel, Katja, Steffen, Björn, Stelljes, Matthias, Teipel, Raphael, von Bonin, Malte, Wagner-Drouet, Eva, Wass, Maxi, and Wendelin, Knut

Abstract

Whether high-dose cytarabine-based salvage chemotherapy, administered to induce complete remission in patients with poor responsive or relapsed acute myeloid leukaemia scheduled for allogeneic haematopoietic stem-cell transplantation (HSCT) after intensive conditioning confers a survival advantage, is unclear.

Published
2024
Full Text
View/download PDF

20. Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial

Author

Hölig, Kristina, Schmidt, Helmuth, Hütter, Gero, Kramer, Michael, Teipel, Raphael, Heidrich, Katharina, Zimmer, Kristin, Heidenreich, Falk, Blechschmidt, Matthias, Torosian, Tigran, Ordemann, Rainer, Kroschinsky, Frank, Rücker-Braun, Elke, Gopsca, Laszlo, Wagner-Drouet, Eva Maria, Oelschlaegel, Uta, Schmidt, Alexander H., Bornhäuser, Martin, Ehninger, Gerhard, and Schetelig, Johannes

Published
2022
Full Text
View/download PDF

22. Treosulfan compared with <scp>reduced‐intensity</scp> busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial

Author

Beelen, Dietrich, Stelljes, Matthias, Reményi, Péter, Wagner‐Drouet, Eva‐Maria, Dreger, Peter, Bethge, Wolfgang, Ciceri, Fabio, Stölzel, Friedrich, Junghanß, Christian, Labussiere‐Wallet, Hélène, Schaefer‐Eckart, Kerstin, Grigoleit, Goetz U., Scheid, Christof, Patriarca, Francesca, Rambaldi, Alessandro, Niederwieser, Dietger, Hilgendorf, Inken, Russo, Domenico, Socié, Gérard, Holler, Ernst, Glass, Bertram, Casper, Jochen, Wulf, Gerald, Basara, Nadezda, Bieniaszewska, Maria, Stuhler, Gernot, Verbeek, Mareike, La Rocca, Ursula, Finke, Jürgen, Benedetti, Fabio, Pichlmeier, Uwe, Klein, Anja, Baumgart, Joachim, Markiewicz, Miroslaw, and Rocca, Ursula La

Subjects
Leukemia, Myeloid, Acute, Transplantation Conditioning, Myelodysplastic Syndromes, Medizin, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Humans, Prospective Studies, Hematology, Middle Aged, Busulfan, Vidarabine, Aged
Abstract

The phase III study was designed to compare event-free survival (EFS) after treosulfan-based conditioning with a widely applied reduced-intensity conditioning (RIC) busulfan regimen in older or comorbid patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). A previously reported confirmatory interim analysis of the randomized clinical study including 476 patients demonstrated statistically significant noninferiority for treosulfan with clinically meaningful improvement in EFS. Here, the final study results and pre-specified subgroup analyses of all 570 randomized patients with completed longer-term follow-up are presented. Patients presenting HCT-specific comorbidity index >2 or aged >= 50 years were randomly assigned (1:1) to intravenous (IV) fludarabine with either treosulfan (30 g/m(2) IV) or busulfan (6.4 mg/kg IV) after stratification by disease risk group, donor type, and participating institution. The primary endpoint was EFS with disease recurrence, graft failure, or death from any cause as events. EFS of patients (median age 60 years) was superior after treosulfan compared to RIC busulfan: 36-months-EFS rate 59.5% (95% CI, 52.2-66.1) vs. 49.7% (95% CI, 43.3-55.7) with a hazard ratio (HR) of 0.64 (95% CI, 0.49-0.84), p = 0.0006. Likewise, overall survival (OS) with treosulfan was superior compared to busulfan: 36-month-OS rate 66.8% vs. 56.3%; HR 0.64 (95% CI, 0.48-0.87), p = 0.0037. Post hoc analyses revealed that these differences were consistent with the confirmatory interim analysis, and thereby the treosulfan regimen appears particularly suitable for older AML and MDS patients.

Published
2022

24. Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Author

Van de Loosdrecht, Arjan A., primary, Cloos, Jacqueline, additional, Wagner-Drouet, Eva-Maria, additional, Platzbecker, Uwe, additional, Holderried, Tobias A.W., additional, van Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Lehmann, Sören, additional, van Zeeburg, Hester J.T., additional, Rovers, Jeroen, additional, and Gjertsen, Bjorn T., additional

Published
2022
Full Text
View/download PDF

25. Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Author

Van de Loosdrecht, Arjan A., primary, Cloos, Jacqueline, additional, Wagner-Drouet, Eva-Maria, additional, Platzbecker, Uwe, additional, Holderried, Tobias A.W., additional, van Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Welters, Marij J.P., additional, van der Burg, Sjoerd H., additional, van Zeeburg, Hester J.T., additional, Rovers, Jeroen, additional, and Gjertsen, Bjorn T., additional

Published
2022
Full Text
View/download PDF

27. Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial

Author

Beelen, Dietrich W., primary, Stelljes, Matthias, additional, Reményi, Péter, additional, Wagner‐Drouet, Eva‐Maria, additional, Dreger, Peter, additional, Bethge, Wolfgang, additional, Ciceri, Fabio, additional, Stölzel, Friedrich, additional, Junghanß, Christian, additional, Labussiere‐Wallet, Hélène, additional, Schaefer‐Eckart, Kerstin, additional, Grigoleit, Goetz U., additional, Scheid, Christof, additional, Patriarca, Francesca, additional, Rambaldi, Alessandro, additional, Niederwieser, Dietger, additional, Hilgendorf, Inken, additional, Russo, Domenico, additional, Socié, Gérard, additional, Holler, Ernst, additional, Glass, Bertram, additional, Casper, Jochen, additional, Wulf, Gerald, additional, Basara, Nadezda, additional, Bieniaszewska, Maria, additional, Stuhler, Gernot, additional, Verbeek, Mareike, additional, La Rocca, Ursula, additional, Finke, Jürgen, additional, Benedetti, Fabio, additional, Pichlmeier, Uwe, additional, Klein, Anja, additional, Baumgart, Joachim, additional, and Markiewicz, Miroslaw, additional

Published
2022
Full Text
View/download PDF

28. Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia

Author

Loke, Justin, primary, Labopin, Myriam, additional, Craddock, Charles, additional, Cornelissen, Jan J., additional, Labussière‐Wallet, Hélène, additional, Wagner‐Drouet, Eva Maria, additional, Van Gorkom, Gwendolyn, additional, Schaap, Nicolaas P.M., additional, Kröger, Nicolaus M., additional, Veelken, Joan Hendrik, additional, Rovira, Montserrat, additional, Menard, Anne Lise, additional, Bug, Gesine, additional, Bazarbachi, Ali, additional, Giebel, Sebastian, additional, Brissot, Eolia, additional, Nagler, Arnon, additional, Esteve, Jordi, additional, and Mohty, Mohamad, additional

Published
2022
Full Text
View/download PDF

29. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany

Author

Bethge, Wolfgang Andreas, primary, Martus, Peter, additional, Schmitt, Michael, additional, Holtick, Udo, additional, Subklewe, Marion, additional, von Tresckow, Bastian, additional, Ayuk, Francis, additional, Wagner-Drouet, Eva Maria, additional, Wulf, Gerald G, additional, Marks, Reinhard, additional, Penack, Olaf, additional, Schnetzke, Ulf, additional, Koenecke, Christian, additional, von Bonin, Malte, additional, Stelljes, Matthias, additional, Glass, Bertram, additional, Baldus, Claudia D, additional, Vucinic, Vladan, additional, Mougiakakos, Dimitrios, additional, Topp, Max S, additional, Fante, Matthias Alexander, additional, Schroers, Roland, additional, Bayir, Lale May, additional, Borchmann, Peter, additional, Buecklein, Veit, additional, Hanoun, Christine, additional, Thomas, Simone, additional, Beelen, Dietrich W., additional, Lengerke, Claudia, additional, Kroeger, Nicolaus, additional, and Dreger, Peter, additional

Published
2022
Full Text
View/download PDF

30. Favourable Outcome after Treosulfan Based Conditioning in Patients Undergoing an Allogeneic Hematopoietic Cell Transplantation (alloHCT) for the Treatment of Acute Myleloid Leukaemia (AML): A Subgroup Analysis of the Randomized Phase III MC-Fludt.14/L Trial

Author

Stölzel, Friedrich, primary, Stelljes, Matthias, additional, Beelen, Dietrich Wilhelm, additional, Markiewicz, Miroslaw, additional, Remenyi, Peter, additional, Dreger, Peter, additional, Ciceri, Fabio, additional, Wagner-Drouet, Eva-Maria, additional, Junghanss, Christian, additional, Scheid, Christoph, additional, Patriarca, Francesca, additional, Socié, Gerard, additional, Hilgendorf, Inken, additional, Rambaldi, Alessandro, additional, Schaefer-Eckart, Kerstin, additional, Russo, Domenico, additional, Grigoleit, Goetz, additional, Wulf, Gerald, additional, Basara, Nadezda, additional, Glass, Bertram, additional, Stuhler, Gernot, additional, Bieniaszewska, Maria, additional, Casper, Jochen, additional, Holler, Ernst, additional, Benedetti, Fabio, additional, Iori, Anna Paola, additional, Trenschel, Rudolf, additional, and Bethge, Wolfgang, additional

Published
2022
Full Text
View/download PDF

32. Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial

Author

Hölig, Kristina, primary, Schmidt, Helmuth, additional, Hütter, Gero, additional, Kramer, Michael, additional, Teipel, Raphael, additional, Heidrich, Katharina, additional, Zimmer, Kristin, additional, Heidenreich, Falk, additional, Blechschmidt, Matthias, additional, Torosian, Tigran, additional, Ordemann, Rainer, additional, Kroschinsky, Frank, additional, Rücker-Braun, Elke, additional, Gopsca, Laszlo, additional, Wagner-Drouet, Eva Maria, additional, Oelschlaegel, Uta, additional, Schmidt, Alexander H., additional, Bornhäuser, Martin, additional, Ehninger, Gerhard, additional, and Schetelig, Johannes, additional

Published
2021
Full Text
View/download PDF

33. Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Author

Bethge, Wolfgang A, primary, Martus, Peter, additional, Schmitt, Michael, additional, Holtick, Udo, additional, Borchmann, Peter, additional, Subklewe, Marion, additional, Rejeski, Kai, additional, von Tresckow, Bastian, additional, Ayuk, Francis A., additional, Kroeger, Nicolaus, additional, Wagner-Drouet, Eva-Maria, additional, Wulf, Gerald, additional, Marks, Reinhard, additional, Penack, Olaf, additional, Schnetzke, Ulf, additional, Koenecke, Christian, additional, Von Bonin, Malte, additional, Stelljes, Matthias, additional, Glass, Bertram, additional, Baldus, Claudia D., additional, Vucinic, Vladan, additional, Mougiakakos, Dimitrios, additional, Topp, Max, additional, Wolff, Daniel, additional, Schroers, Roland, additional, Thomas, Simone, additional, Beelen, Dietrich W., additional, Lengerke, Claudia, additional, and Dreger, Peter, additional

Published
2021
Full Text
View/download PDF

34. An investigation of the diagnostic, predictive, and prognostic impacts of three colonic biopsy grading systems for acute graft versus host disease

Author

Kreft, Andreas, primary, Hippe, Katrin, additional, Wagner-Drouet, Eva Maria, additional, Ries, Isabelle, additional, Kandulski, Arne, additional, Büttner-Herold, Maike, additional, Neumann, Helmut, additional, Weber, Daniela, additional, Holler, Ernst, additional, and Schindeldecker, Mario, additional

Published
2021
Full Text
View/download PDF

35. Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Author

Hess, Georg, Vucinic, Vladan, Rejeski, Kai, Aydilek, Enver, Simon, Linda, Penack, Olaf, Koenecke, Christian, von Bonin, Malte, von Tresckow, Bastian, Fehr, Martin, Pott, Christiane, Stilgenbauer, Stephan, Leng, Corinna, Schroers, Roland, Duell, Johannes, Marks, Reinhard, Mueller, Fabian, Brunnberg, Uta, Kerkhoff, Andrea, Ohler, Anke, Wagner Drouet, Eva-Maria, Schmidtmann, Irene, Theobald, Matthias, Dreyling, Martin, and Dreger, Peter

Published
2023
Full Text
View/download PDF

36. Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation

Author

Wolff, Daniel, Wagner-Drouet, Eva Maria, Teschner, Daniel, Wolschke, Christine, Schäfer-Eckart, Kerstin, Gärtner, Johannes, Mielke, Stephan, Schreder, Martin, Kobbe, Guido, Hilgendorf, Inken, Klein, Stefan, Verbeek, Mareike, Ditschkowski, Markus, Koch, Martina, Lindemann, Monika, Schmidt, Traudel, Rascle, Anne, Barabas, Sascha, Deml, Ludwig, and Wagner, Ralf

Subjects
ddc:610, lcsh:R5-920, immune monitoring, immunosuppression, 610 Medizin, Medizin, CMV, T cells, CMV-specific cellular immunity, hematopoietic stem cell transplantation, recall antigen, peptide, IFN-γ ELISpot, antigen processing and presentation, virus diseases, Article, lcsh:Medicine (General)
Abstract

Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality following hematopoietic stem cell transplantation (HSCT). Measuring CMV-specific cellular immunity may improve the risk stratification and management of patients. IFN-γ ELISpot assays, based on the stimulation of peripheral blood mononuclear cells with CMV pp65 and IE-1 proteins or peptides, have been validated in clinical settings. However, it remains unclear to which extend the T-cell response to synthetic peptides reflect that mediated by full-length proteins processed by antigen-presenting cells. We compared the stimulating ability of pp65 and IE-1 proteins and corresponding overlapping peptides in 16 HSCT recipients using a standardized IFN-γ ELISpot assay. Paired qualitative test results showed an overall 74.4% concordance. Discordant results were mainly due to low-response tests, with one exception. One patient with early CMV reactivation and graft-versus-host disease, sustained CMV DNAemia and high CD8+ counts showed successive negative protein-based ELISpot results but a high and sustained response to IE-1 peptides. Our results suggest that the response to exogenous proteins, which involves their uptake and processing by antigen-presenting cells, more closely reflects the physiological response to CMV infection, while the response to exogenous peptides may lead to artificial in vitro T-cell responses, especially in strongly immunosuppressed patients.

Published
2021

37. Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Author

Schuler, Esther, Wagner-Drouet, Eva-Maria, Ajib, Salem, Bug, Gesine, Crysandt, Martina, Dressler, Sabine, Hausmann, Andreas, Heidenreich, Daniela, Hirschbühl, Klaus, Hoepting, Matthias, Jost, Edgar, Kaivers, Jennifer, Klein, Stefan, Koldehoff, Michael, Kordelas, Lambros, Kriege, Oliver, Müller, Lutz P., Rautenberg, Christina, Schaffrath, Judith, Schmid, Christoph, Wolff, Daniel, Haas, Rainer, Bornhäuser, Martin, Schroeder, Thomas, and Kobbe, Guido

Subjects
Salvage Therapy, Sulfonamides, Transplantation Conditioning, Hematopoietic Stem Cell Transplantation, Correction, Kaplan-Meier Estimate, DNA Methylation, Allografts, Bridged Bicyclo Compounds, Heterocyclic, Decitabine, Combined Modality Therapy, Thrombocytopenia, Leukemia, Myeloid, Acute, Leukocyte Count, Recurrence, Germany, Myelodysplastic Syndromes, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Drug Evaluation, Humans, Tumor Lysis Syndrome, Immunosuppressive Agents, Febrile Neutropenia, Retrospective Studies
Abstract

Treatment of relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT) remains a great challenge. Aiming to evaluate the combination of venetoclax and hypomethylating agents (HMAClax) for the treatment of relapse of myeloid malignancies after alloHSCT, we retrospectively collected data from 32 patients treated at 11 German centers. Venetoclax was applied with azacitidine (n = 13) or decitabine (n = 19); 11 patients received DLI in addition. HMAClax was the first salvage therapy in 8 patients. The median number of cycles per patient was 2 (1-19). All but 1 patient had grade 3/4 neutropenia. Hospital admission for grade 3/4 infections was necessary in 23 patients (72%); 5 of these were fatal. In 30 evaluable patients, overall response rate (ORR) was 47% (14/30, 3 CR MRD

Published
2021

38. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents : A retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Author

Schuler, Esther, Wagner-Drouet, Eva-Maria, Jost, Edgar, Kaivers, Jennifer, Klein, Stefan, Koldehoff, Michael, Kordelas, Lambros, Kriege, Oliver, Müller, Lutz P., Rautenberg, Christina, Schaffrath, Judith, Schmid, Christoph, Ajib, Salem, Wolff, Daniel, Haas, Rainer, Bornhäuser, Martin, Schroeder, Thomas, Kobbe, Guido, German Cooperative Transplant Study Group, Bug, Gesine, Crysandt, Martina, Dressler, Sabine, Hausmann, Andreas, Heidenreich, Daniela, Hirschbühl, Klaus, and Hoepting, Matthias

Subjects
Oncology, medicine.medical_specialty, Myeloid, medicine.medical_treatment, Azacitidine, Medizin, Decitabine, Salvage therapy, Hypomethylating agents, Hematopoietic stem cell transplantation, Neutropenia, Venetoclax, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Medicine, ddc:610, Relapse, Hematology, business.industry, General Medicine, medicine.disease, medicine.anatomical_structure, chemistry, 030220 oncology & carcinogenesis, Allogeneic hematopoietic stem cell transplantation, Original Article, DLI, business, 030215 immunology, medicine.drug
Abstract

Annals of hematology 100(4), 959-968 (2021). doi:10.1007/s00277-020-04321-x, Published by Springer, Berlin ; Heidelberg ; New York

Published
2021

41. A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Author

Schmitz, Norbert, primary, Truemper, Lorenz H, additional, Bouabdallah, Krimo, additional, Ziepert, Marita, additional, Leclerc, Mathieu, additional, Cartron, Guillaume, additional, Jaccard, Arnaud, additional, Reimer, Peter, additional, Wagner-Drouet, Eva Maria, additional, Wilhelm, Martin, additional, Sanhes, Laurence, additional, Lamy, Thierry, additional, de Leval, Laurence, additional, Rosenwald, Andreas, additional, Roussel, Murielle, additional, Kroschinsky, Frank P, additional, Lindemann, Walter Walter, additional, Dreger, Peter, additional, Viardot, Andreas, additional, Milpied, Noel J, additional, Gisselbrecht, Christian, additional, Wulf, Gerald G, additional, Gyan, Emmanuel, additional, Gaulard, Philippe, additional, Bay, Jacques-Olivier, additional, Glass, Bertram, additional, Poeschel, Viola, additional, Damaj, Gandhi, additional, Sibon, David, additional, Delmer, Alain Jacques, additional, Bilger, Karin, additional, Banos, Anne, additional, Haenel, Mathias, additional, Dreyling, Martin, additional, Metzner, Bernd, additional, Keller, Ulrich, additional, Braulke, Friederike, additional, Friedrichs, Birte, additional, Nickelsen, Maike, additional, Altmann, Bettina, additional, and Tournilhac, Olivier, additional

Published
2020
Full Text
View/download PDF

42. Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT

Author

Giebel, Sebastian, primary, Labopin, Myriam, additional, Socié, Gerard, additional, Beauvais, David, additional, Klein, Stefan, additional, Wagner-Drouet, Eva Maria, additional, Blaise, Didier, additional, Nguyen-Quoc, Stephanie, additional, Bourhis, Jean Henri, additional, Thiebaut, Anne, additional, Labussière-Wallet, Hélène, additional, Charbonnier, Amandine, additional, Berceanu, Ana, additional, Diez-Martin, José Luis, additional, Fegueux, Nathalie, additional, Esteve, Jordi, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2020
Full Text
View/download PDF

43. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

Author

Weissinger, Eva M., primary, Metzger, Jochen, additional, Schleuning, Michael, additional, Schmid, Christoph, additional, Messinger, Diethelm, additional, Beutel, Gernot, additional, Wagner-Drouet, Eva-Maria, additional, Schetelig, Johannes, additional, Baurmann, Herrad, additional, Rank, Andreas, additional, Stolzl, Friedrich, additional, Schäfer-Eckart, Kerstin, additional, Westphal, Karin, additional, Bethge, Wolfgang, additional, von Harsdorf, S., additional, Bunjes, Donald W., additional, Heidenreich, Daniela, additional, Klein, Stefan, additional, Holler, Ernst, additional, Kreipe, Hans H., additional, Jonigk, Danny, additional, Türüchanow, Irina, additional, Raad, Julia, additional, Papkalla, Armin, additional, von der Leyen, Heiko, additional, Hambach, Lothar, additional, Hamwi, Iyas, additional, Ehrlich, Steve, additional, Krauter, Jurgen, additional, Stadler, Michael, additional, and Ganser, Arnold, additional

Published
2020
Full Text
View/download PDF

44. Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial

Author

Hölig, Kristina, primary, Schmidt, Helmuth, additional, Hütter, Gero, additional, Kramer, Michael, additional, Teipel, Raphael, additional, Heidrich, Katharina, additional, Zimmer, Kristin, additional, Heidenreich, Falk, additional, Blechschmidt, Matthias, additional, Torosian, Tigran, additional, Ordemann, Rainer, additional, Kroschinsky, Frank, additional, Rücker-Braun, Elke, additional, Gopsca, Laszlo, additional, Wagner-Drouet, Eva Maria, additional, Oelschlaegel, Uta, additional, Schmidt, Alexander H., additional, Bornhäuser, Martin, additional, Ehninger, Gerhard, additional, and Schetelig, Johannes, additional

Published
2020
Full Text
View/download PDF

46. Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Author

Schuler, Esther, primary, Wagner-Drouet, Eva-Maria, additional, Ajib, Salem, additional, Bug, Gesine, additional, Crysandt, Martina, additional, Dressler, Sabine, additional, Hausmann, Andreas, additional, Heidenreich, Daniela, additional, Hirschbühl, Klaus, additional, Hoepting, Matthias, additional, Jost, Edgar, additional, Kaivers, Jennifer, additional, Klein, Stefan A, additional, Kordelas, Lambros, additional, Kriege, Oliver, additional, Mueller, Lutz Peter, additional, Rautenberg, Christina, additional, Schaffrath, Judith, additional, Schmid, Christoph, additional, Wolff, Daniel, additional, Bornhaeuser, Martin, additional, Schroeder, Thomas, additional, and Kobbe, Guido, additional

Published
2019
Full Text
View/download PDF

47. 94 - Favourable Outcome after Treosulfan Based Conditioning in Patients Undergoing an Allogeneic Hematopoietic Cell Transplantation (alloHCT) for the Treatment of Acute Myleloid Leukaemia (AML): A Subgroup Analysis of the Randomized Phase III MC-Fludt.14/L Trial

Author

Stölzel, Friedrich, Stelljes, Matthias, Beelen, Dietrich Wilhelm, Markiewicz, Miroslaw, Remenyi, Peter, Dreger, Peter, Ciceri, Fabio, Wagner-Drouet, Eva-Maria, Junghanss, Christian, Scheid, Christoph, Patriarca, Francesca, Socié, Gerard, Hilgendorf, Inken, Rambaldi, Alessandro, Schaefer-Eckart, Kerstin, Russo, Domenico, Grigoleit, Goetz, Wulf, Gerald, Basara, Nadezda, Glass, Bertram, Stuhler, Gernot, Bieniaszewska, Maria, Casper, Jochen, Holler, Ernst, Benedetti, Fabio, Iori, Anna Paola, Trenschel, Rudolf, and Bethge, Wolfgang

Published
2022
Full Text
View/download PDF

48. Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens

Author

Beelen, Dietrich, primary, Markiewicz, Miroslaw, additional, Stelljes, Matthias, additional, Remenyi, Peter, additional, Wagner-Drouet, Eva-Maria, additional, Dreger, Peter, additional, Bethge, Wolfgang, additional, Ciceri, Fabio, additional, Stölzel, Friedrich, additional, Junghanß, Christian, additional, Michallet, Mauricette, additional, Schaefer-Eckart, Kerstin, additional, Grigoleit, Goetz, additional, Scheid, Christof, additional, Patriarca, Francesca, additional, Mico, Maria Caterina, additional, Niederwieser, Dietger, additional, Hilgendorf, Inken, additional, Russo, Domenico, additional, Socié, Gerard, additional, Holler, Ernst, additional, Glass, Bertram, additional, Wulf, Gerald, additional, Basara, Nadezda, additional, Hellmann, Andrzej, additional, Stuhler, Gernot, additional, Verbeek, Mareike, additional, Iori, Anna Paola, additional, Finke, Jürgen, additional, Benedetti, Fabio, additional, and Casper, Jochen, additional

Published
2019
Full Text
View/download PDF

50. Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1gene mutations. A study by the Acute Leukemia Working Party of the EBMT

Author

Giebel, Sebastian, Labopin, Myriam, Socié, Gerard, Beauvais, David, Klein, Stefan, Wagner-Drouet, Eva Maria, Blaise, Didier, Nguyen-Quoc, Stephanie, Bourhis, Jean Henri, Thiebaut, Anne, Labussière-Wallet, Hélène, Charbonnier, Amandine, Berceanu, Ana, Diez-Martin, José Luis, Fegueux, Nathalie, Esteve, Jordi, Nagler, Arnon, and Mohty, Mohamad

Abstract

The presence of IKZF1gene mutations is associated with poor prognosis of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The goal of this retrospective study was to evaluate outcome of allogeneic hematopoietic cell transplantation (allo-HCT) in this population. Ninety-five patients transplanted in first (n= 75) or second (n= 20) complete remission (CR) from either HLA-matched sibling (n= 32), unrelated (n= 47) or haploidentical (n= 16) donor were included in the analysis. The probabilities of the overall survival (OS) and leukemia-free survival (LFS) at 2 years were 55% and 47%, respectively. Relapse incidence (RI) was 32% while non-relapse mortality (NRM), 21%. The incidence of grade II–IV acute graft-versus-host disease (GVHD) and chronic GVHD was 34% and 30%, respectively. The probability of GVHD and relapse-free survival (GRFS) was 35%. In a multivariate analysis positive minimal residual disease (MRD) status was associated with decreased chance of LFS (HR = 3.15, p= 0.004) and OS (HR = 2.37, p= 0.049) as well as increased risk of relapse (HR = 5.87, p= 0.003). Disease stage (CR2 vs. CR1) affected all, LFS, OS, GRFS, RI, and NRM. Results of allo-HCT for patients with BCP-ALL and IKZF1mutations are generally improving, however, individuals with detectable MRD have poor prognosis and require additional intervention prior to transplantation.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results